SCHEMBL4930499

SCHEMBL4930499

Cc1cc(O)c(Cl)cc1N1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.51
HSP90AB1 P08238 3/20 0.51
ADRB1 P08588 6/20 0.47
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
DRD2 P14416 2/20 0.44
DRD3 P35462 2/20 0.44
ALDH1A1 P00352 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
HTR7 P34969 1/20 0.41
HTR1A P08908 1/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30609616 0.86 ADRB1 (0.53) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL17884970 0.86 ADRB1 (0.53) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL23216866 0.79 ADRB1 (0.53) HSP90AA1HSP90AB1ADRB1HTR3EHTR3B
SCHEMBL5577182 0.78 HSP90AA1 (0.36) HSP90AA1HSP90AB1ALDH1A1
SCHEMBL17884850 0.77 ALDH1A1 (0.50) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL30609651 0.77 ALDH1A1 (0.50) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL470221 0.77 ADRB1 (0.47) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL2366486 0.76 ADRB1 (0.57) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL2872887 0.74 HTR3A (0.57) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL23239831 0.73 ADRB1 (0.47) HSP90AA1HSP90AB1ADRB1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 HSP90AA1 1750/4885HSP90AB1 1172/4885ADRB1 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.